NasdaqCM - Nasdaq Real Time Price
USD
Dermata Therapeutics, Inc. (DRMA)
1.1950
-0.0050
(-0.42%)
As of 9:41:49 AM EDT. Market Open.
Loading chart for DRMA
- Previous Close
1.2000 - Open
1.2000 - Bid 0.8640 x 200
- Ask 1.5300 x 200
- Day's Range
1.1800 - 1.2300 - 52 Week Range
1.1000 - 9.9000 - Volume
26,148 - Avg. Volume
2,082,503 - Market Cap (intraday)
4.806M - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-8.1600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
www.dermatarx.comRecent News: DRMA
View More
Performance Overview: DRMA
Trailing total returns as of 4/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
DRMA
48.49%
S&P 500 (^GSPC)
5.15%
1-Year Return
DRMA
87.93%
S&P 500 (^GSPC)
14.50%
3-Year Return
DRMA
99.38%
S&P 500 (^GSPC)
58.01%
5-Year Return
DRMA
99.99%
S&P 500 (^GSPC)
61.52%
Earnings Trends: DRMA
View MoreAnalyst Insights: DRMA
View MoreStatistics: DRMA
View MoreValuation Measures
As of 4/1/2026
-
Market Cap
4.83M
-
Enterprise Value
-2.70M
-
Trailing P/E
0.09
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
--
-
Price/Book (mrq)
0.78
-
Enterprise Value/Revenue
--
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-85.25%
-
Return on Equity (ttm)
-194.20%
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
-7.56M
-
Diluted EPS (ttm)
-8.1600
Balance Sheet and Cash Flow
-
Total Cash (mrq)
7.52M
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
-5.02M
Compare To: DRMA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: DRMA
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
